SUNNYVALE, Calif., July 25, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today installation of the CyberKnife® Robotic Radiosurgery System at five renowned academic oncology centers in Europe and the United States, including the Penn Medicine at Pennsylvania Hospital in Philadelphia, PA; The Royal Marsden Hospital in London, England; The Barts Cancer Center at St. Bartholomew's Hospital in London, England; Charite University in Berlin, Germany; and Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch in Gliwice, Poland. Backed by solid clinical evidence for a wide range of treatment applications, including prostate and lung cancer, the CyberKnife System empowers these leading centers to offer minimally invasive radiosurgical treatment options for patients with even the most complex tumors.
"Adoption of the CyberKnife System at these prestigious academic medical centers known for offering patients the most innovative and state-of-the-art options for cancer treatment is further validation of CyberKnife as the premier system for dedicated radiosurgery," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray Incorporated. "Accuray is proud to work with a growing number of academic centers around the world that are advancing the use of radiosurgery beyond intracranial applications to treat patients with a wide range of indications and breaking new ground in both research and patient care."
"We chose the CyberKnife System